CALCIMEDICA INC SEC Filings

CalciMedica insider activity: Eric W. Roberts, identified as Chief Business Officer, Director and 10% owner, reported transactions on 09/15/2025. The Form 4 shows an open-market purchase of 3,400 shares at a weighted average price of $2.6779 (price range $2.65–$2.70). The filing also records a disposition of 179,706 shares and multiple indirect holdings reported through custodians and affiliated SPVs, including positions held by FMTC Custodian (81,650), Oppenheimer (49,894), IRA Financial Trust (10,661) and several Valence Investments SPVs (356,989; 66,228; 316,109). The explanation clarifies the weighted average purchase price and offers to provide per-price purchase breakdowns on request.

Eric W. Roberts, Chief Business Officer, director and 10% owner of CalciMedica, Inc. (CALC), reported transactions on a Form 4. On 09/12/2025 a purchase of 5,000 shares of Common Stock was reported at $3.12 per share. The form also reports a disposition of 179,706 shares and multiple indirect holdings across custodial and SPV accounts, with a listed post-transaction beneficial ownership figure of 78,250 shares in one entry. The filing was signed by an attorney-in-fact on 09/15/2025.

CalciMedica insider purchase and holdings summary. Eric W. Roberts, who is listed as a director, a 10% owner and Chief Business Officer, reported a purchase of 2,343 shares of CalciMedica common stock on 09/09/2025 at a weighted average price of $3.1488 (price range $2.75–$3.21). The filing lists total beneficial ownership following the reported transactions across multiple accounts and entities: 73,250 shares (FMTC Custodian Roth IRA), 179,706 shares disposed, 49,894 shares (Oppenheimer custodian Roth IRA), 10,661 shares (IRA Financial Trust), 356,989 shares (Valence Investments SPV IV, LLC), 66,228 shares (Valence Investments SPV V, LLC), and 316,109 shares (Valence Investments SPV VI, LLC). The filer signed through an attorney-in-fact.

CalciMedica, Inc. Schedule 13G/A clarifies that a group led by Avenue Venture Opportunities Fund II and affiliated entities reports beneficial ownership of 1,359,553 shares, representing 8.87% of the issuer on a fully diluted basis (13,972,177 shares). The reported position includes 718,390 shares issuable upon conversion of a $2.0 million loan and 641,163 shares issuable upon exercise of warrants.

The Loan and Security Agreement closed on February 28, 2025 for up to $32 million in three tranches; Tranche I funded at closing, Tranche II is available between September 1, 2025 and March 31, 2026 and remained unfunded at the amendment date. The amendment reports that the actual number of common shares held as of the filing is 1,000,358 shares and clarifies conversion rights and voting/dispositive power among the reporting persons.

CalciMedica, Inc. disclosed that a group led by Avenue Venture Opportunities Fund II, L.P. beneficially owns 1,359,553 shares of common stock, representing 8.87% of the fully diluted class based on 13,972,177 shares. The reported holdings include 718,390 shares issuable upon conversion of a $2.0 million loan convertible at a per‑share price of $2.784 and 641,163 shares issuable upon exercise of outstanding warrants. Avenue Capital Management II, L.P. is the manager with sole voting and dispositive power over the Fund's shares but disclaims direct beneficial ownership except to the extent of pecuniary interest. The filing provides required ownership disclosure and related certifications.

CalciMedica insider activity: Eric W. Roberts, listed as Chief Business Officer, Director and a 10% owner, reported purchases of common stock on 08/28/2025 and 08/29/2025 totaling 10,000 shares acquired (9,200 at a weighted-average price of $2.863 and 800 at $2.74). The filing lists multiple indirect beneficial holdings across custodians and vehicles, including positions held by FMTC Custodian - Roth IRA, Oppenheimer & Co. Custodian, IRA Financial Trust Company, Valence Investments SPV IV/V/VI, and others, with several large indirect balances reported. The form also shows a disposition of 179,706 shares. The filer certified the report via attorney-in-fact signature on 09/02/2025.

CalciMedica insider transaction summary: Director and Chief Business Officer Eric W. Roberts reported transactions in CalciMedica (CALC) on 08/21/2025. The filing shows a purchase of 3,508 shares at a weighted average price of $2.7928 (price range $2.75–$2.80). The form also reports a disposition of 179,706 shares. After the reported purchase, Mr. Roberts beneficially owns multiple blocks of common stock across accounts and entities, including 60,907 shares held by an FMTC Custodian Roth IRA, 49,894 shares via Oppenheimer custodian Roth IRA, and additional holdings through Valence Investments SPV entities totaling hundreds of thousands of shares. The form was signed by an attorney-in-fact on 08/25/2025.

CalciMedica insider filing shows purchases and an option exercise increasing reported holdings. Eric W. Roberts reported purchases of 1,000 shares on 08/19/2025 at $2.79 and 2,000 shares on 08/20/2025 at $2.72. He also exercised an employee stock option for 15,000 shares at an exercise price of $1.53 on 08/20/2025.

The filing lists multiple custodial and indirect holdings across Roth IRA accounts and several Valence Investments SPVs, and shows 57,750 derivative securities reported as beneficially owned following the transactions.

CalciMedica insider purchase reported: The company's Chief Medical Officer, Sudarshan Hebbar, reported buying 9,563 shares of CalciMedica, Inc. (ticker: CALC) on 08/19/2025 at a weighted average purchase price of $2.8194, with individual trade prices ranging from $2.74 to $2.86. After the transaction, the reporting person beneficially owned 61,539 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/21/2025 and discloses that breakdowns by price per lot are available upon SEC staff request.